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Background: Prior data indicate increased perioperative morbidity and mortality in patients receiving induction
chemoradiotherapy before pneumonectomy for lung cancer.
Objective: We reviewed a consecutive series of pneumonectomies to determine the impact of induction therapy
on operative mortality.
Results:Over a 15-year period, 183 patients underwent pneumonectomy for lung cancer. Forty-six received com-
bined preoperative radiochemotherapy (25.2%), and 137 patients underwent resection only. Indications for
induction therapy were stage IIB disease in 1, IIIA in 35, IIIB in 8, and IV in 2 patients. Patients receiving
induction therapy were younger (mean age 58.4 vs 61.9 years; P ¼ .033), had less heart disease (6.5 vs
26.3%;P¼ .0035), higher preoperative forced expiratory volume in 1 second (2.48 vs 2.13 L; P¼ .0018), a lower
rate of endobronchial tumor (34.8 vs 67.2%; P ¼ .0002), and underwent intrapericardial procedures more often
(71.7 vs 43.1%; P ¼ .0011). Hospital mortality was 4.3% (2/46) after preoperative therapy and 6.6% (9/137)
after resection only (P¼ .73); the difference in cardiopulmonary morbidity was not significant (51.1% vs 40.4%;
P ¼ .22). Induction did not predict hospital mortality after adjustment for a propensity score derived from non-
operative and operative variables correlated with neoadjuvant therapy.
Conclusions: A regimen of induction radiation and chemotherapy does not increase the operative mortality of
pneumonectomy in carefully selected patients.As the most extensive anatomic lung resection, pneumonec-
tomy has the highest operative mortality. The administration
of preoperative adjuvant therapy before pneumonectomy is
controversial because of the potential to increase this risk.
Trimodality therapy was, for example, associated with
high mortality in a phase II multi-institutional prospective
randomized trial, particularly for right-sided procedures.1
Conversely, patients with locally advanced lung cancer
stand to receive the greatest benefit of additional up-front
tumor therapy, and limiting patients with large tumors and
N2 disease to surgical resection first risks progression to
systemic disease.
We2 have used combined radiotherapy and chemotherapy
for the preoperative treatment of N2 disease and selected
other indications since the late 1980s2 and reviewed
our experience during a period of consistent application of
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METHODS
Medical records of a consecutive series of patients with lung cancer
undergoing pneumonectomy by the Division of Thoracic Surgery at Massa-
chusetts General Hospital were reviewed. Complex procedures were ex-
cluded as outlined in Figure 1. The Partners Human Research Committee
approved the study. Demographic data, preoperative pulmonary function,
and scintigraphic ventilation–perfusion data were obtained. Comorbid con-
ditions were recorded.Hypertensionwas defined as taking antihypertensive
medication to lower blood pressure, diabetes mellitus as taking oral or par-
enteral medications to lower blood sugar, and congestive heart failure as
past hospital admissions at any time or taking diuretics or angiotensin-con-
verting enzyme inhibitors for this diagnosis or having symptoms related to
reduced left ventricular ejection fraction. Coronary artery disease was
defined as a past myocardial infarction or evidence of myocardial ischemia
by electrocardiogram or stress testing or known stenosis after cardiac cath-
eterization. Renal failure was defined as a creatinine level above 1.6 mg/dL
and peripheral vascular disease as the presence of symptoms of claudica-
tion or past surgical or catheter-based intervention for this indication. The
diagnoses of cerebrovascular accident or transient ischemic attack were
assumed after permanent or temporary focal neurologic deficits. Patients un-
derwent computed tomography (CT) of the chest, evaluation of the brain by
either CT or magnetic resonance imaging, and either bone scan or, since its
inception, positron emission tomography. With the exception of patients
referred to Massachusetts General Hospital after combined induction, all
patients were evaluated by a thoracic surgeon before treatment, almost
always including mediastinoscopy. No mediastinoscopy was repeated after
induction therapy; restaging occurred with CT.
Neoadjuvant preoperative treatment consisted of combined chemother-
apy and radiation. There was no uniform protocol during the study period,ardiovascular Surgery c Volume 138, Number 2 289
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CT ¼ computed tomography
FEV1 ¼ forced expiratory volume in 1 second
and numerous patients were treated at outside institutions; however, the
standard preoperative radiation dose was administered in 25 fractions
over a period of 5 weeks, in combination with chemotherapy, limiting the
dose to the main bronchus to 45 Gy. We have used a higher radiation
dose (54 Gy) in selected extensive tumors. Some patients were referred after
neoadjuvant therapy having received doses in excess of 60 Gy. At Massa-
chusetts General Hospital, there was a change from 2- to 3-dimensional con-
formal radiotherapy in 2001. Patients with prior cervical or mediastinal
radiation for other indications were excluded.
The perioperative management was standardized regarding routine use
of epidural catheters, intravenous fluid restriction, operative use of vasoac-
tive drugs, and low tidal volumes during 1-lung anesthesia. A chest catheter
was placed at the conclusion of the operation in all patients and removed
either immediately after extubation or the next day. Intraoperative parame-
ters studied were total duration, blood loss, transfusion requirement, epidu-
ral pain control, intraoperative hypotension, and operating room extubation.
Postoperative variables examined were reintubation, adult respiratory
distress syndrome, pneumonia, pulmonary embolism, pulmonary edema,
empyema, bronchopleural fistula, myocardial infarction, atrial fibrillation,
ventricular fibrillation, congestive heart failure (grouped as major cardiopul-
monary events), duration of mechanical ventilation, tracheostomy, reopera-
tion, deep vein thrombosis, neurologic complication, and gastrointestinal
complication. The hospital mortality was determined.
Tumors were staged according to published revisions of the international
lung cancer staging system.3 The resection was complete if specimen mar-
gins, including bronchial, vascular, and soft tissue margins, were found to
be free of tumor.
Statistical Analysis
Univariate analysis was conducted by Fisher’s exact test for binary vari-
ables and the Wilcoxon exact test for continuous variables. The variables
selected for calculation of a propensity score4 included all nonoperative
and operative variables correlatedwith induction therapy or mortality in uni-
variate analyses (except for highly correlated measurements, for example,
forced expiratory volume in 1 second (FEV1) and forced vital capacity,
when only one was used).290 The Journal of Thoracic and Cardiovascular SuThe propensity score was calculated as follows:
p ¼ expðLÞ=ð1 þ exp½LÞ
Where L is a linear function:
L ¼7.106461þ0.008476 age0.290960 l1þ0.19304 l2 0.152798
l32.096960 l41.513946 l5þ1.015116 pN classifier0.797669 pT clas-
sifierþ0.687062 FEV1þ0.035041 DLCO%þ0.400145 l6þ0.023664 l7
þ1.580099 l8þ1.854619 l9þ1.995547 l10þ0.917844 RBC packs
l1 ¼ 1 if male sex, 0 otherwise
l2 ¼ 1 if renal disease present, 0 otherwise
l3 ¼ 1 if hypertension present, 0 otherwise
l4 ¼ 1 if CAD or CHF present, 0 otherwise
l5 ¼ 1 if bronchial tumor mass present, 0 otherwise
l6 ¼ 1 if FEV1 is missing, 0 otherwise
l7 ¼ 1 if DLCO% is missing, 0 otherwise
l8 ¼ 1 if intrapericardial procedure, 0 otherwise
l9 ¼ 1 if beta-blockers were used during operation, 0 otherwise
l10 ¼ 1 if extubation after operation was immediate, 0 otherwise.
CAD¼ coronary artery disease; CHF¼ congestive heart failure; DLCO
¼ carbon monoxide diffusion capacity; FEV1¼ forced expired volume in 1
second; absorbed radiation dose; RBC ¼ red blood cell; T, N ¼ TNM clas-
sifier; pT, pN ¼ pathologic T resp. N.
The coefficients in the above linear function are maximum likelihood
estimates obtained by logistic regression.
To determine whether induction therapy predicted hospital mortality, we
used the propensity score as a variable in a logistic regression along with in-
duction therapy.
RESULTS
From September 1993 to December 2007, 183 consec-
utive patients underwent pneumonectomy for non–small
cell carcinoma of the lung at Massachusetts General Hos-
pital. Their mean age was 61.1 years and 114 (62.3%)
were male. Comorbidity was present in 109 (59%) pa-
tients: hypertension in 43%, coronary artery disease or
congestive heart failure in 21%, diabetes mellitus in
7.7%, and steroid use in 6.0%. Eleven patients had re-
ceived oral steroid therapy, 9 for reactive airway disease,
1 for radiation pneumonitis, and 1 after liver transplanta-
tion. Table 1 lists demographics and preoperativePneumonectomy for primary lung
cancer, all types:  260 patients 
Excluded 77
Completion 32
Carinal 18
Chest wall 18
Extrapleural 2
Cardiopulmonary bypass 1
General Surgical Service 3
Unrelated  radiation 3
Standard Pneumonectomy 183
Resection only 137 Induction therapy 46
FIGURE 1. Composition of study group and excluded patients.rgery c August 2009
Gaissert et al Point/Counterpointparameters for patients with and without preoperative
therapy. Patients receiving preoperative treatment were
younger, had fewer cardiac comorbidities, and had better
lung function. Mediastinoscopy preceded resection in
96% of patients.
Preoperative Therapy
Forty-six (25.1%) of 183 patients received combined
mediastinal radiation and chemotherapy. The clinical stage
of patients treated with induction therapy was IIB in 1,
IIIA in 35, IIIB in 8 (T4 in 2, N3 in 6), and IV in 2 patients.
The chemotherapy regimen was cisplatinum/vinorelbine/5-
fluorouracil in 20 patients, carboplatin/taxol in 17, cisplati-
num/VP16 in 4, cisplatinum/taxol in 1, cisplatinum/VP16/
taxotere in 1, and was not recorded in 3. Complications of
chemotherapy occurred in 11 patients, including neutrope-
nia in 5, pneumonia in 3, and severe nausea in 3. The median
radiation dose was 45 Gy (range 42–72 Gy), but preopera-
tive therapy rarely exceeded 54 Gy. Radiation was compli-
cated by pneumonitis in 3, esophagitis in 7, and important
dysphagia in 2 patients.
Resection
In the induction group, 24 patients underwent left and 22
right pneumonectomy, whereas no neoadjuvant therapy was
given to 52 having right-sided and 85 having left-sided
resections. Table 2 lists operative parameters. Patients
receiving induction had a higher proportion of intrapericar-
dial procedures, required a greater number of transfusions,
were more likely to receive beta-blockers, and less often
had a bronchial mass on endoscopy.
Operative Events
The estimated median blood loss as determined from an-
esthesia records was 300 mL; estimated blood loss exceeded
1000 mL in 10 patients. Twenty-five (13.7%) patients
received intraoperative red blood cell transfusions. Bron-
chial stump coverage with vascularized tissue was described
in all but 3 patients and consisted in the induction group of
intercostal muscle in 23, pericardial fat in 10, omentum in 6,
latissimus muscle in 4, and pleura in 3. All but 8 patients
were extubated in the operating room; blood loss in 3 of
these was 1000 mL or greater. Median operating time was
290 minutes.
Pathologic Results
The histologic type of carcinoma was squamous in 95,
adenocarcinoma in 73, large cell in 8, adenosquamous in
6, and bronchioalveolar in 1. The pathologic stage is listed
in Table 3. Eight patients had M1 disease as a result of either
solitary brain metastasis (3 patients) or ipsilateral carcinoma
of identical histologic type in a separate lobe (5 patients:
adenocarcinoma 4 and adenosquamous 1). Microscopically
positive margins were identified in 9 (4.9%) resections.The Journal of Thoracic and CHilar soft tissue was positive in 5, the perivascular margin
in 2, and the atrial margin in 1 patient. There were no grossly
incomplete (R2) resections. In the induction group, 9 (19.5
%) of 46 patients had a complete pathologic response.
Mortality and Morbidity
The overall hospital mortality was 6.0% (11/183). There
was no hospital death during the last 5 years of the study
period. Table 4 lists the procedure-specific mortality. Hospi-
tal mortality for right pneumonectomy was higher than for
left pneumonectomy, but induction therapy was not associ-
ated with increased mortality. No patient with stage IV dis-
ease and 1 patient with stage IIIB (T4 N0) died.
Causes of hospital death are given in Table 5. Adult respi-
ratory distress syndrome or postpneumonectomy pulmonary
edema in 4 patients was the leading cause of death. Hospital
morbidity is listed in Table 6. A bronchopleural fistula was
confirmed in 5 patients (2.7%, 2 right and 3 left), of whom 1
received induction therapy and 2 died during hospitalization.
The only difference in the rates of individual or combined
cardiopulmonary morbidities was a higher tracheostomy
rate in the induction group (8.9% vs 1.5%; P ¼ .034).
Multivariate Analysis
The nonoperative and operative variables that entered in
the multivariable model and predicted induction therapy
were the absence of a bronchial tumor mass (P ¼ .0019),
TABLE 1. Demographic data and nonoperative risk factors
Variable
No
induction
Induction
therapy
P
value
No. 137 46
Age, y (mean  SD 61.9  11.5 58.4  10.0 .0334
Male gender (%) 62.8 60.9 .8613
Hypertension (%) 43.8 39.1 .6094
Diabetes (%) 7.3 8.7 .7530
Steroid use (%) 5.8 6.5 1.0000
CHF (%) 8.8 0.0 .0391
CAD (%) 21.2 6.5 .0247
CAD or CHF (%) 26.3 6.5 .0035
Renal failure (%) 2.9 4.3 .6421
Peripheral vascular disease (%) 8.0 8.7 1.0000
Cerebrovascular accident (%) 6.6 4.3 .7331
Transient ischemic attack (%) 2.2 2.2 1.0000
Preoperative hematocrit  SD 37.9  4.6 35.2  4.1 <.0001
Preoperative radiotherapy (%) 0 91.4 <.0001
FEV1  SD 2.13  0.71 2.48  0.64 .0018
FEV1  SD (%) 70.6  19.6 80.5  19.0 .0026
FVC  SD 3.02  0.96 3.41  0.84 .0187
DLCO  SD (%) 69.6  19.0 78.5  19.4 .0721
Scintigraphy
Perfusion in remaining lung (%) 67.5  14.0 63.5  9.4 .1574
Ventilation in remaining lung (%) 62.7  15.0 58.0  9.0 .1193
SD, Standard deviation; CHF, congestive heart failure; CAD, coronary artery disease;
FEV1, forced expiratory volume in 1 second; DLCO, carbon monoxide diffusion ca-
pacity.ardiovascular Surgery c Volume 138, Number 2 291
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(P ¼ .0022), the absence of coronary artery disease or con-
gestive heart failure (P ¼ .015), intraoperative beta-blocker
use (P ¼ .015), more units of blood transfused (P ¼ .016),
and higher carbon monoxide diffusion capacity (odds ratio
1.04; P ¼ .017). Age, sex, renal disease, hypertension,
FEV1, and immediate extubation did not predict induction
therapy. The propensity score was entered, as a variable,
in a logistic regression for hospital mortality. Induction ther-
apy did not predict hospital mortality, after adjustment for
propensity score (Table 7).
Induction therapy remained nonpredictive for hospital
mortality when this model was adjusted for additional vari-
ables. Hypertension, present in 45% of survivors and only
9.1% of operative deaths (P ¼ .026), modestly lowered
the odds of mortality (Table 8).
When only nonoperative or preoperative variables were
entered in this model to determine the propensity score,
induction therapy again failed to predict operative death.
TABLE 2. Operative variables in patients with and without induction
therapy
No induction
(n ¼ 137)
Induction therapy
(n ¼ 46)
Variable % n % n P value
Mediastinoscopy 96.4 132 93.5 43 .4167
Bronchial tumor mass 67.2 92 34.8 16 .0002
Epidural pain control 99.3 136 100.0 46 1.0000
Right pneumonectomy 38.0 64 47.8 48 .2976
Intrapericardial procedure 43.1 59 71.1 33 .0011
Total duration (min  SD) 288  90 314  108 .2685
Operative hypotension 19.4 19.6 1.0000
Operative beta-blocker use 7.8 21.7 .0154
Operative vasopressor use 62.8 63.0 1.0000
Extubation in OR 95.6 95.7 1.0000
Total blood loss
(mL  SD)
371  261 445  371 .2087
RBC units (SD) 0.19  0.63 0.70  1.72 .0057
Mean duration of
intubation (days  SD)
1.16  0.44 1.13  0.34 .7836
pT classifier 2.40  0.64 2.11  0.61 .0124
pN classifier 0.82  0.64 1.25  0.89 .0017
SD, Standard deviation;OR, operating room; RBC, red blood cell; pT pN, pathologic T
resp. N.
TABLE 4. Procedure-specific mortality
Hospital mortality
Type of pneumonectomy No. of procedures % No. of deaths
Total group 183 6.0 11
Induction therapy 46 4.3 2
Resection only 137 6.6 9
Right, induction therapy 22 4.5 1
Right, resection only 52 11.5 6
Left, induction therapy 24 4.2 1
Left, resection only 85 3.5 3292 The Journal of Thoracic and Cardiovascular SuDISCUSSION
There is disagreement concerning whether neoadjuvant
therapy raises the operative risk of pneumonectomy. In con-
trast to several retrospective studies that found increased
respiratory complications5 but no increase in mortality after
induction chemotherapy,6,7 a recent prospective randomized
study, Southwest Oncology Group phase II 8805, examining
induction trimodality therapy, reported a higher operative
mortality, in particular after right pneumonectomy.1 Other
retrospective studies8-10 also reported risks for pneumonec-
tomy that exceeded a recently reported 6%mortality of stan-
dard pneumonectomy in the Society of Thoracic Surgeons
Thoracic Database.11 The preliminary analysis of intergroup
trial 0139 found an early mortality of 24% after right pneu-
monectomy.12 These reports overlap with existing knowl-
edge of increased operative mortality and morbidity after
resection of the right lung in comparison with left-sided pro-
cedures.13 The awareness of this risk is expected to influence
the choice and sequence of multimodality therapy for locally
advanced lung cancer and may narrow already limited treat-
ment options. However, the attribution of higher mortality
rates to preoperative therapy is not conclusive; institution-
specific selection criteria for pneumonectomy, extent of
evaluation of comorbidity, and use of surgical strategies to
TABLE 3. Pathologic stage after pneumonectomy
No induction Induction therapy
Stage I
T2 N0 21 9
Stage II
T1 N1 1 1
T2 N1 52 7
T3 N0 14 0
Stage IIIA
T3 N1 16 0
T1-3 N2 17 16
Stage IIIB
T4 N0-2 10 1
T2 N3 0 1
Stage IV
Any M1 6 2
Complete response 9
TABLE 5. Causes of hospital death
Cause No induction Induction therapy
Adult respiratory distress syndrome 3 1
Bronchopleural fistula 2 —
Myocardial infarction 2 —
Right heart failure — 1
Pneumonia 1 —
Pulmonary hypertension 1 —
Hemorrhage — 1
Ventricular fibrillation 1 —
In 2 patients, two causes contributing to death were listed.rgery c August 2009
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are difficult to capture and compare. Finally, the avoidance
of pneumonectomy and trimodality therapy may lead to
higher locoregional recurrence and lower survival.
In this retrospective analysis of pneumonectomy for lung
cancer, neither operative mortality nor morbidity was
increased in patients who received induction therapy before
pneumonectomy for lung cancer. The effects of patient
selection, demonstrated by the lower age and rates of comor-
bidity in the induction group, are obvious and appropriate to
reduce operative risk. Propensity score analysis suggests,
however, that the comorbid condition itself, and not neoad-
juvant therapy, imparts risk under the existing conditions of
patient selection. The result of this study supports the contin-
ued use of trimodality therapy before pneumonectomy and
emphasizes the importance of rigorous and careful preoper-
ative cardiopulmonary evaluation of operative candidates
and meticulous operative technique.
On the basis of our results in patients with stage IIIA N2
disease in 1991,2 we have preferred and continue to recom-
mend to combine preoperative radiation and chemotherapy
for clinical stage IIIA and selected stage II disease. Absence
of disease in mediastinal lymph nodes after complete resec-
tion has proved in this and the Southwest Oncology Group
8805 study (in 10/42 patients, 24%,2 vs 19/89 patients,
21%1) to be the strongest predictor of long-term survival.
In addition to N2 disease, this approach included selected
patients with large hilar tumors owing to concern for positive
margins at the mediastinum. The complete response rate in
the present study, 19.5%, is comparable with those in the
TABLE 6. Hospital mortality and morbidity in patients with and
without induction therapy
No induction
(n ¼ 137)
Induction therapy
(n ¼ 46)
Variable n % n % P value
Death 9 6.6 2 4.3 .7331
ARDS 10 7.4 6 13.3 .2329
Pneumonia 15 11.0 7 15.6 .4351
Reintubation 12 8.8 5 11.4 .5672
Pulmonary edema 9 6.6 0 0.0 .1148
Bronchopleural fistula 4 2.9 1 2.2 1.0000
Empyema 5 3.7 1 2.2 1.0000
Reoperation 11 6.6 7 15.6 .1265
Pulmonary embolism 1 0.7 1 2.2 .4365
Tracheotomy 2 1.5 4 8.9 .0343
Myocardial infarction 3 2.2 0 0.0 .5750
Ventricular fibrillation 4 2.9 2 4.3 .6394
Congestive heart failure 4 2.9 1 2.2 1.0000
Atrial fibrillation 34 25.0 17 37.8 .1258
GI complications 7 5.1 4 8.9 .47
Neurologic events 8 5.9 4 8.9 .4963
Combined cardiopulmonary
complications
55 40.4 23 51.1 .2278The Journal of Thoracic and Caforementioned studies. We have carefully selected these
candidates for neoadjuvant radiochemotherapy and find
our process validated. Given a selective approach to trimo-
dality therapy, patients are not exposed to any greater oper-
ative risk by induction, a result similar to studies examining
chemotherapy only.5-7 The value of multimodality therapy
in the case of pneumonectomy continues to be debated as
the proportion of patients in prospective randomized studies
is often small so that results rarely reflect consistent selection
and surgical strategy.
Right pneumonectomy with or without preoperative
cytoreductive therapy remains a formidable operation with
important early postoperative risks. In our study, standard
pneumonectomy had a 3-fold higher hospital mortality on
the right than on the left despite younger patient age, con-
firming the results of others.10,13 Potential causes for such
imbalanced laterality risk include the greater threat of lym-
phatic outflow obstruction during right-sided lymph node
dissections and the larger mass of the right lung. Paren-
chyma-sparing resections, furthermore, appear to thin out
the ranks of candidates for right-sided resections more than
on the left; in our earlier report of sleeve lobectomy, more
than three fourths (78%) were right-sided procedures.14
Others also have reported a higher number of right-sided
sleeve resections15 and left pneumonectomies.13,15 Thus,
the remaining right-sided tumors may consist of a selected
group of larger, more invasive lesions in patients who may
not tolerate preoperative therapy owing to comorbidity.
Our study has important limitations. First, the induction
group in our study is small and may cause us to underesti-
mate effects of induction on mortality. Further, neither we
nor other investigators noted earlier include an analysis of
candidates specifically rejected for this surgical procedure.
Thus, the size and the survival of the rejected group are
unknown, although we may infer that their survival is short.
Our study also did not examine the precise tally of intraoper-
ative and postoperative fluid management thought to be
TABLE 7. Logestic regression for hospital mortality
Variable OR 95% CI P value
(Intercept) 0.059 0.025–0.136 <.0001
One unit of propensity score 3.074 0.180–52.387 .4377
Induction therapy 0.387 0.048–3.123 .3728
OR, Odds ratio; CI, confidence interval.
TABLE 8. Odds of mortality
Variable OR 95% CI P value
Renal disease 58.637 3.291 – 1044.9 0.0056
Hypertension 0.049 0.003 - 0.870 0.0399
Immediate extubation 0.045 0.005 - 0.426 0.0068
RBC packs 1.417 0.741 - 2.708 0.2918
One unit of
propensity score
8.463 0.126 - 566.8 0.3194
Induction therapy 0.072 0.002 - 2.548 0.1483ardiovascular Surgery c Volume 138, Number 2 293
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and postpneumonectomy pulmonary edema; in retrospective
analysis, however, the precision for these variables is weak
at best. The study period further encompassed important
changes in patient management, the emphasis on intraoper-
ative pressure control ventilation and the introduction of
radiation techniques limiting exposure of the contralateral
lung among them, reflected in a lack of operative deaths in
the last 5 years. The changes were not the subject of our anal-
ysis but require separate study.
The selection of patients for induction therapy before
pneumonectomy reflected in our results is also obvious in
reports of preoperative high-dose (60 Gy) mediastinal radi-
ation and chemotherapy that were achieved with periopera-
tive mortality rates comparable with lower, standard
radiation doses.9,16,17 Median age in two of these studies
was below 50 years, and mean FEV1 was above 2.4 L in
one. Stringent preoperative evaluation, careful operative
technique including protection of the bronchial stump,17
and a postoperative management dedicated to the particular
risks of induction, even using elective postoperative
mechanical ventilation,16 may also explain these favorable
results. Other factors including surgeon experience and hos-
pital volume18,19 have been associated with the operative
outcome of pneumonectomy. Patient age, in contrast, may
pose a less flexible limit to the benefits of careful selection,
inasmuch as Mizushima and associates20 found an 8-fold in-
crease in operative mortality of pneumonectomy in patients
over the age of 70 years. In our experience, patients receiv-
ing induction therapy were younger, but there was no differ-
ence in age between hospital survivors and patients who
died. Patients with cardiopulmonary complications, how-
ever, were 5 years older than those without. Retrospective
studies cannot be expected to disentangle the complexities
of institutional selection and management, but may inform
about the relative impact of risk factors.
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